Physicians' Academy for Cardiovascular Education
The European Commission (EC) has approved the use of evolocumab in patients with established atherosclerotic CVD (MI, stroke, PAD) to reduce CV risk.
A Google-driven nocebo effect may underlie statin intolerance, as countries with many websites on statin side-effects showed a higher prevalence of statin intolerance.
VBWG at ACC 2018 Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.
Inhibition of hepatic PCSK9 synthesis with the small interfering RNA inclisiran led to significant reductions of non-HDL-c and apoB, and increases of HDL-c, which were sustained up to day 180.
VBWG at ACC 2018 In a debate about muscle symptoms in patients on statins, Thompson defended the statement that these symptoms are real by discussing the results of several clinical trials and studies examining the biochemical mechanism.
Based on objective and critical appraisal of the literature on potential adverse effects of statins, the EAS Consensus Panel concludes that statin treatment is remarkably safe.
In the largest and longest study with bempedoic acid thus far, treatment resulted in 20% additional on-treatment LDL-C lowering on maximally tolerated statin, and hsCRP reduction of 22%.
New ORION-data shows inclisiran has a one-size-fits-all dosing regimen of 300 mg on day 1, day 90 and every six months thereafter, across a wide range of dyslipidemia patients, including HoFH.
Patients with a history of MI who are closer to their most recent event, have had multiple prior MIs or have residual multi-vessel CAD, had higher CV risk reductions with evolocumab.
Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.
Prof. Paul Ridker discusses the insights that originate from the CANTOS trial, in which reducing inflammation with canakinumab reduced CV events. These findings have implications for the management of residual risk.
Mendelian randomization study suggests that lowering LDL affects large artery atherosclerosis, but not small artery occlusion or cardioembolic stroke, while increasing HDL may benefit small artery disease.
